Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients
Publication date: Available online 26 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Eman Z. Kandeel, Ghada El Sayed, Nahla Elsharkawy, Dalia Negm Eldin, Hanan R. Nassar, Dalia Ibrahiem, Randa Amin, Marwa Hanafi, Mohamed Khalil, Azza KamelAbstractBackgroundThe significance of FMS-like tyrosine kinase 3 (FLT3)-ITD mutation in acute myeloid leukemia (AML) prognosis has been well established. The aims of this study were to investigate the prognostic impact of the FLT3 protein (CD135) expression and its association with FLT3-ITD mutation, and to identify its role in minimal residual disease.Patients and Metho...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Aseptic Meningitis as a Complication of Daratumumab Therapy
Publication date: Available online 28 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kimaya Reddy, Myo Htut, Amrita Krishnan, Sanjeet S. Dadwal (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
ConclusionEven in CR patients, outcomes were improved by an intensified approach with HDT-ASCT consolidation and lenalidomide-based maintenance therapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
ConclusionThese data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Hypomethylating Agents-associated Infections—Systematic Review and Meta-analysis of Randomized Controlled Trials
ConclusionTreatment with HMAs was associated with an increase in the grade 3/4 infection rate. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma
ConclusionAlthough the overall risk of SCs in patients with HL declined after modifications in HL treatment, the risk did not change significantly at most individual sites. Thus, close follow-up with active surveillance for SCs is crucial for long-term survivors of HL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia
ConclusionWe conclude that WM cells produce CCL-3 and possibly enhance the production of RANKL in the bone microenvironment. The correlation of sRANKL and CCL-3 with survival reveals the importance of these cytokines in disease biology and highlights the significance of the interactions between WM and stromal cells for the development of WM. Finally, these findings provide the rationale for the use of anti-RANKL and anti–CCL-3 drugs in animal models of WM before their clinical evaluation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Editorial Board
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Table of Contents
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Giuseppe Saglio, Giora Sharf, Antonio Almeida, Andrija Bogdanovic, Felice Bombaci, Jelena Čugurović, Nigel Deekes, Valentín Garcia-Gutiérrez, Jan de Jong, Šarūnas Narbutas, Peter Westerweel, Daniela ZackovaAbstractTreatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal for patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. Although guidance is now available, patients’ questions...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Steven M. Bair, Anthony Mato, Jakub SvobodaAbstractClassical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional approach to treatment has consisted of chemotherapy, radiation, and for those who relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpo...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis
The objective of the study was to evaluate through meta-analysis the pooled proportions of patients responding to each therapeutic agent. We conducted a systematic review and meta-analysis to estimate the pooled response rate to modern hairy cell leukemia therapies. Articles published between January 1992 and August 2017 were identified by searching PubMed, Web of Science, and the Cochrane Library. Weighted meta-analysis of proportion using a random-effects model was performed for each treatment option. Of 3287 articles viewed, 20 articles describing 21 studies were included in the meta-analysis. The pooled random effect o...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma
ConclusionOverall, data from the PANEX trial support regulatory approval of panobinostat plus bortezomib and dexamethasone and suggest the potential tolerability benefits of subcutaneous bortezomib in this regimen. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Serum Free Light Chain Difference and β2 Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis
ConclusionThe incidence of thromboembolism was substantial in those with AL amyloidosis. A greater FLC difference and for β2MG levels were risk factors for thromboembolic events. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
ConclusionSC Btz is associated with better tolerance; however, IV administration achieves a faster and deeper response in Chinese patients with newly-diagnosed multiple myeloma. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma
ConclusionExtralymphatic disease in patients with Hodgkin lymphoma is a rare occurrence (16%) associated with poor clinical outcome. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Treating Adult Acute Lymphoblastic Leukemia in Brazil—Increased Early Mortality Using a German Multicenter Acute Lymphoblastic Leukemia-based regimen
ConclusionIntensified chemotherapy protocols for adult ALL have succeeded in achieving better survival rates in adults, especially younger adults. The low overall survival found with GMALL in Brazil's public hospital denotes the importance of optimizing the adaptations of international protocols for treatment of ALL in nondeveloped countries and, in parallel, improving supportive care in public services. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Raja Pramanik, Anudishi Tyagi, Anita Chopra, Akash Kumar, Sreenivas Vishnubhatla, Sameer BakhshiAbstractBackgroundThe purpose of our study was to evaluate the clinical, cytogenetic, and molecular features, and survival outcomes in patients with acute myeloid leukemia (AML) with myeloid sarcoma (MS) and compare them with patients with AML without MS.Patients and MethodsThis was a retrospective analysis of de novo pediatric AML patients with or without MS diagnosed at our cancer center between June 2003 and June 2016....
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study
ConclusionElevated ferritin at diagnosis may indicate tumor burden in patients with AML and predict worse EFS in the high-risk group. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Cytogenetic Profile of Moroccan Pediatric Acute Lymphoblastic Leukemia: Analysis of 155 Cases With a Review of the Literature
ConclusionThe frequency of most chromosomal rearrangements successfully identified in our study and their lineage correlated with those reported in the published data. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
ConclusionThe present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
ConclusionEntospletinib monotherapy at 800 mg twice daily demonstrated limited activity in patients with advanced, relapsed DLBCL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
ConclusionThe combination of bortezomib and vorinostat is safe and has modest activity in MCL and limited activity in DLBCL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Bone Health and Survival in Women with Multiple Myeloma
ConclusionHigher fracture risk, measured by FRAX, was associated with higher MM mortality in post-menopausal women, independent of many other clinical factors. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis
In conclusion, mutations in IDH, SRSF2, and ASXL1 had worse prognosis in OS with HRs around 2. JAK2 and SRSF2 mutation were not associated with increased leukemia transformation. The adverse effect of triple-negative, which was often compared with CALR mutation, needs to be explored. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study
This study aimed to evaluate correlates of TKI NA using EM and test the diagnostic accuracy of subjective adherence measures.Patients and MethodsCML patients receiving a TKI for any duration were enrolled at 4 hematology institutes, and adherence was measured for 4 months. EM adherence was the reference adherence measure, expressed as the percentage of days with the drug taken as prescribed. Subjective adherence was measured using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) self-report and clinician-reported visual analog scale (VAS) at 2 time points. Baseline theory–derived corr...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Prevalence of Monoclonal Gammopathy of Undetermined Significance in India—A Hospital-based Study
ConclusionTo the best of our knowledge, the present study is the first systematic study on the prevalence of MGUS in an Indian population. The overall prevalence of MGUS was 1.43% in the evaluated Indian cohort, lower than that reported for white and black populations. The incidental detection of 6 subjects with multiple myeloma of 3429 screened subjects in our study was high compared with the reported incidence of multiple myeloma in India of only 1.9 per 100,000 persons. This finding indicates the need to create awareness about myeloma-related symptoms and screening studies in appropriate age groups, at least in the hosp...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

FLT3-TKD mutations associated to NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia
Publication date: Available online 13 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Marielle Perry, Sarah Bertoli, Clément Rocher, Sandrine Hayette, Sophie Ducastelle, Fiorenza Barraco, Hélène Labussière-Wallet, Gilles Salles, Christian Recher, Xavier Thomas, Etienne PaubelleAbstractOutcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial. Herein we present a retrospective study of 126 newly diagnosed AML patients performed in two French centers. FLT3-TKD mutations represented 12.7% of patients, whil...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Hodgkin Lymphoma With Multiple Autoimmune Disorders: Case Report and Review of the Literature
Publication date: Available online 15 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Natalie S. Grover, Christopher E. Dittus, Alice D. Ma, Steven I. Park (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Interim PET-CT result is not predictive of survival in patients with MYC-rearranged non-Burkitt aggressive B cell lymphoma
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma
Publication date: Available online 15 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Leslie Padrnos, Brenda Ernst, Amylou C. Dueck, Heidi E. Kosiorek, Brenda F. Ginos, Angela Toro, Patrick B. Johnston, Thomas M. Habermann, Jose F. Leis, Joseph R. Mikhael, Grzegorz S. Nowakowski, Joseph Colgan, Luis Porrata, Stephen M. Ansell, Thomas E. Witzig, Craig ReederSummaryTreatment outcomes have improved in lymphoid malignancies but relapse remains inevitable in most patients. Everolimus (RAD) and lenalidomide (LEN) have shown clinical activity as single agents in patients with relapsed and refractory (R/R) Hodgki...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

A Pilot Trial of Lirilumab with or without Azacitidine for patients with Myelodysplastic Syndrome
ConclusionLirilumab either as a single as well as in combination with azacitidine has clinical activity in MDS. Further studies are needed to confirm our findings. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Venetoclax in combination with bortezomib, dexamethasone and daratumumab for multiple myeloma
Publication date: Available online 18 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kian J. Rahbari, Jason D. Nosrati, Tanya M. Spektor, James R. Berenson (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

A Review of Small Molecules and Their Therapeutic Targets
Publication date: Available online 18 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hanley N. AbramsonAbstractTreatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation (ASCT), has changed dramatically in the past 20 years as three new classes of small molecule drugs (arbitrarily defined as having molecular weights of less than 900 kDa) - immunomodulators (IMiDs), proteasome inhibitors (PIs), and histone deacetylase (HDAC) blockers - have been introduced for the disease. Therapeutic options for MM expa...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL
Publication date: Available online 19 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Linyu Li, Xuhan Zhang, Tingting Zhang, Zheng Song, Ge Hu, Wei Li, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianming Liu, Lixia Feng, Yi Pan, Qiongli Zhai, Bin Meng, Xiubao Ren, Kai Fu, Ping Wang, Xianhuo Wang, Huilai ZhangAbstractBackgroundDouble-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 e...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Multiple Myeloma Patients Ineligible for Randomized Controlled Trials have Poorer Outcomes Irrespective of Treatment
Publication date: Available online 21 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Mk Malecek, Ma Fiala, Ma Schroeder, J. Dukeman, A. Ghobadi, Ke Stockerl-Goldstein, Ta Wildes, R. Vij (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

The Effect of Adherence-Enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): a Quasi-Experimental Pre-Post Intervention Multicenter Pilot Study
Publication date: Available online 25 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Avi Leader, Noam Benyamini, Anat Gafter – Gvili, Juliet Dreyer, Bronya Calvarysky, Alina Amitai, Osnat Yarchovsky-Dolberg, Giora Sharf, Eric Tousset, Opher Caspi, Martin Ellis, Itai Levi, Sabina De Geest, Pia RaananiAbstractBackgroundNon-adherence to tyrosine kinase inhibitors in chronic myeloid leukemia is associated with inferior outcomes. Scarce evidence exists on effectiveness of adherence enhancing interventions. This pilot study aimed to evaluate the feasibility and effectiveness of an intervention to improve...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, non-interventional study
ConclusionOur prospective study reveals huge diversity in treatments used to manage MM in real-life practice, linked to factors such as novel-agent accessibility and evolving treatment recommendations, and provides insight into associated clinical benefits. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

The evidence for and against green tea and turmeric in the management of Chronic Lymphocytic Leukemia
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Erin Bange, Colleen Timlin, Charlene Kabel, Jakub Svoboda, Lindsey Roeker, Anthony R. MatoAbstractComplementary and alternative medicine (CAM) is a diverse group of medical and health care systems, practices, and products that are not generally considered part of conventional medicine1. Chronic lymphocytic leukemia (CLL) is the most common leukemia diagnosed in the western hemisphere2 and 16.5-66% of patients report using CAM. The majority of patients use spiritual/mind-body techniques as well as high doses of vitamins a...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Sustained remission of γδ T-cell lymphoma by graft-versus-lymphoma effect which relapsed early after cord blood transplantation
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Ryo Ichinohasama, Hideo HarigaeAbstractA 53-year-old male suffering from fever, multiple skin nodules and gastric ulcer had been diagnosed as a rare and aggressive subtype of malignant lymphoma with a γδ T-cell phenotype. Cord blood transplantation was performed after achievement of a certain disease control by some courses of chemotherapy. Unfortunately lymphoma relapsed as early as two months after transplantation; however, it has been successfully and cont...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

The utility of PET-CT for the evaluation of patients with peripheral T-cell lymphoma
ConclusionsOur study shows that 90% of PTCL are FDG avid. Yet, PET/CT was not predictive for PFS or OS at any time point. The only predictive factor was lymphopenia. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Clinical Activity of Pralatrexate in Patients with Cutaneous T-Cell Lymphoma Treated with Varying Doses of Pralatrexate
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Francine M. Foss, Terri L. Parker, Michael Girardi, Anlong LiSummaryCutaneous T-cell lymphomas (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Treatment options for CTCL are limited by the their efficacy and tolerability profile. Pralatrexate has demonstrated efficacy in T-cell lymphomas, however dose-modifying adverse events, such as mucositis have occurred. We retrospectively reviewed clinical responses and toxicity in 27 CTCL patients treated with pralatrexate at doses ranging from 10-30mg/...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and are Surrogates for Response to Therapy
ConclusionsThe results of this study show that in patients with CLL Binet clinical stages are good outcome predictors throughout the course of the disease, and also suggest that changes in Binet clinical stage may be useful as response surrogates and to divide the IWCLL PR category into different prognostic subgroups. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Andrew Hantel, Wendy Stock, Satyajit KosuriAbstractMinimal residual disease (MRD) testing in acute myeloid leukemia is increasingly being used to assess treatment response and stratify the risk of relapse for individual patients. Molecular methods for MRD testing began with PCR-based assays for individual recurrent mutations. To date, there is robust evidence for testing NPM1, CBFB-MYH11, and RUNX1/RUNXT1 mutations using this approach, though the best timing and threshold level for each mutation varies. More recent appro...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients with Myelofibrosis: A Case Series
Publication date: Available online 28 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aaron Gerds, Derrick Su, Anastasia Martynova, Benjamin Pannell, Sudipto Mukherrjee, Caitlin O’Neill, Mikkael Sekeres, Casey O’ConnellAbstractMyelofibrosis (MF) is one of the classic myeloproliferative neoplasms (MPNs) and can occur de novo or following transformation from polycythemia vera (PPV MF) or essential thrombocythemia (PET MF). It can be associated with constitutional symptoms and splenomegaly, both of which can greatly affect quality of life. The only curative option for MF is allogeneic stem cell t...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
ConclusionThese results from an integrated analysis support a favorable benefit-risk profile of ibrutinib in patients with CLL/SLL and MCL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Prognostic factors and outcomes in adults with secondary hemophagocytic lymphohistiocytosis: a single-center experience
ConclusionIn this series of adults with HLH, patients with nosocomial infections and neurological symptoms had a statistically significant worse OS. It is the largest series in Latin America, the most common cause of HLH was T-cell lymphoma. In our population, NM-HLH presented a higher mortality. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Management of Newly Diagnosed Older AML Patients Unfit for Traditional Therapy
Publication date: Available online 30 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alan K. Burnett (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Alex F. Herrera, Arturo MolinaAbstractAntibody–drug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigen–antibody interactions to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity and simultaneously minimize off-target toxicity. The earliest ADCs provided disappointing results in the clinic; however, the lessons learned regarding t...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research